Pivotal Study of the CapsoCam Colon (CV-3) in Detecting Colonic Polyps, Using Colonoscopy as the Reference

NCT ID: NCT04607746

Last Updated: 2025-07-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1337 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-06

Study Completion Date

2025-02-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety and effectiveness of the CapsoCam Colon (CV-3) endoscope system for the detection of colonic polyps.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The first phase of the study investigated the first generation of the capsule. The second generation capsule will be investigated in the final phase of enrollment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colonic Polyp

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Data collected from this study investigated the first generation CV-3 capsule.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm study

Subjects swallows the investigational device and undergoes a colonoscopy

Group Type EXPERIMENTAL

Capsule Endoscope

Intervention Type DEVICE

Capsule endoscope used to view colonic mucosa

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capsule Endoscope

Capsule endoscope used to view colonic mucosa

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 45-75 years of age
2. Committed to undergo a colonoscopy, independent of this study
3. Choose to participate and must have signed the IRB-approved informed consent document and agreed to release colonoscopy images and results report to Sponsor

Exclusion Criteria

1. Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps
2. Has contraindication for capsule endoscopy or colonoscopy
3. Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome
4. Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease
5. History of incomplete colonoscopy
6. Type I or uncontrolled II Diabetes (Uncontrolled defined as HbA1C\>6.4 within the past 3 months and/or with history of constipation or gastroparesis.)
7. Impaired cardiac function assessed as greater than NYHA Class II
8. History of small- or large-bowel obstructive condition
9. Known history of swallowing disorder, and/or ischemic bowel disease neuropathies and/or radiation enteritis
10. Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a regular basis that, in the opinion of the Investigator, would put the subject at greater risk for capsule endoscope retention
11. Known allergy to ingredients used in bowel preparation and boosters
12. Daily and/or regular narcotic use
13. Decompensated cirrhosis
14. Prior abdominal radiation therapy
15. Diagnosis of anorexia or bulimia
16. History of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the Investigator believes should exclude the patient from study participation
17. Known or suspected megacolon
18. Scheduled to undergo MRI examination within 7 days after ingestion of the capsule
19. Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis
20. Pregnant or nursing or is of child-bearing potential and does not practice medically acceptable methods of contraception. WOCBP must have a negative urine pregnancy test at screening.
21. Unable to follow or tolerate fasting, bowel preparation, and other study procedures
22. Any documented medical or psychological condition or significant concurrent illness which, in the Investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results
23. Are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study
24. Chronic constipation as defined by \<3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Capso Vision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Shields, MD

Role: PRINCIPAL_INVESTIGATOR

Gastroenterology Consultant at San Mateo County Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Scottsdale, Arizona, United States

Site Status

Gastro Care Institute

Lancaster, California, United States

Site Status

inSite Digestive Health Care

Los Gatos, California, United States

Site Status

Knowledge Research Center

Orange, California, United States

Site Status

Kaiser Permanente Northern California

San Leandro, California, United States

Site Status

Advanced Research Institute

New Port Richey, Florida, United States

Site Status

Digestive and Liver Center of Florida

Orlando, Florida, United States

Site Status

Advanced Gastroenterology Associates, LLC

Palm Harbor, Florida, United States

Site Status

Advanced Research Institute

St. Petersburg, Florida, United States

Site Status

Digestive Health Services

Downers Grove, Illinois, United States

Site Status

Northshore Center for Gastroenterology

Libertyville, Illinois, United States

Site Status

Suburban Gastroenterology

Naperville, Illinois, United States

Site Status

Southwest Gastroenterology

New Lenox, Illinois, United States

Site Status

Digestive Health Specialists

Chelmsford, Massachusetts, United States

Site Status

West Michigan Clinical Research Center

Wyoming, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Hattiesburg GI Associates

Hattiesburg, Mississippi, United States

Site Status

NY total Medical Care, PC

Brooklyn, New York, United States

Site Status

Gastroenterology Group of Rochester

Rochester, New York, United States

Site Status

Great Lakes Gastroenterology Research

Mentor, Ohio, United States

Site Status

Tri-Cities Gastroenterology

Kingsport, Tennessee, United States

Site Status

Vilo Research Group

Houston, Texas, United States

Site Status

Gastroenterology Consultants of SW Virginia

Roanoke, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLN-CVI-5794

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AI Colorectal Polyp Detection
NCT04979962 COMPLETED NA